|Table of Contents|

Expression of CRBN gene in diffuse large B-cell lymphoma and its relationship with MAPK signaling pathway

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 01
Page:
103-109
Research Field:
Publishing date:

Info

Title:
Expression of CRBN gene in diffuse large B-cell lymphoma and its relationship with MAPK signaling pathway
Author(s):
ZHOU Xueru1; 2; FENG Jianglong1; LUO Yunfeng1; DENG Pangjuan1; YANG Wenxiu1
1.Department of Pathology,Guizhou Medical University,Guizhou Guiyang 550004,China;2.Beijing Jishuitan Hospital Guizhou Hospital,Guizhou Guiyang 550014,China.
Keywords:
lenalidomide; diffuse large B-cell lymphoma; CRBN; MAPK; efficacy
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2024.01.018
Abstract:
Objective:To investigate the expression of CRBN gene in diffuse large B-cell lymphoma (DLBCL) and its relationship with MAPK signaling pathway.Methods:GEO,GEPIA and TCGA databases were used to analyze the function of CRBN (target of lenalidomide) in DLBCL and its relationship with related signaling pathways.Fifty-seven DLBCL patients were diagnosed and treated with lenalidomide from January 2016 to October 2020 were collected.The protein expression of CRBN,MAPK were detected by immunohistochemical staining (IHC) and multiple immunofluorescence assay.Results:Bioinformatics data analysis showed that CRBN affected cell proliferation and immune microenvironment through MAPK signaling pathway.CRBN and MAPK were highly expressed in DLBCL,and the expression of CRBN was positively correlated with the expression of MAPK (P＜0.05).Patients with high expression of CRBN and MAPK were easy to benefit from lenalidomide treatment (P＜0.05).Conclusion:CRBN may play a role in the development of DLBCL through MAPK signaling pathway,and the expression of CRBN and MAPK proteins can be used as a reference for the evaluation of lenalidomide.

References:

［1］ DI ROCCO A,DE ANGELIS F,ANSUINELLI M,et al.Is now the time formolecular driven therapy for diffuse large B-cell lymphoma［J］.Expert Rev Hematol,2017,10(9):761-774.
［2］ SCHMITZ R,WRIGHT GW,HUANG DW,et al.Genetics and pathogenesis of diffuse large B-cell lymphoma［J］.N Engl J Med,2018,378(15):1396-1407.
［3］ LANDSBURG DJ,PETRICH AM,ABRAMSON JS,et al.Impact of oncogene rearrangement patterns on outcomes in patients with double-hit no-Hodgkin lymphoma［J］.Cancer,2016,122(4):559-564.
［4］ 王丽萍,冯江龙,李品浩,等.CRBN、MUM1、C-MYC、BCL-2在弥漫性大B细胞淋巴瘤中的表达及与来那度胺疗效的关系［J］.现代肿瘤医学,2022,30(24):4490-4495. WANG LP，FENG JL，LI PH，et al.Relationship between the expressions of CRBN,MUM1,C-MYC,BCL-2 in diffuse large B-cell lymphoma and the efficacy of lenalidomide［J］.Modern Oncology,2022,30(24):4490-4495.
［5］ GRIBBEN JG,FOWLER N,MORSCHHAUSER F.Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma［J］.Clin Oncol,2015,33(25):2803-2811.
［6］ 王蒙,张平平,袁媛,等.标准化R-CHOP方案联合来那度胺治疗弥漫大B细胞淋巴瘤效果研究［J］.中国标准化,2022，66(22):302-304. WANG M,ZHANG PP,YUAN Y，et al.Effect of standardized R-CHOP regimen combined with lenalidomide in the treatment of diffuse large B-cell lymphoma［J］.China Standardization,2022，66(22):302-304.
［7］ LACY SE,BARRANS SL,BEER PA,et al.Targeted sequencing in DLBCL,molecular subtypes,and outcomes:a Haematological Malignancy Research Network report［J］.Blood,2020,135(20):1759-1771.
［8］ HEIDER M,EICHNER R,STROH J,et al.The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma［J］.Mol Cell，2021，81(6):1170-1186.
［9］ 王丽，施继敏.18F-FDG PET/CT检测初发DLBCL患者骨髓浸润的应用价值［J］.实用肿瘤杂志，2018,33（5）：480-485. WANG L,SHI JM.Application value of 18F-FDG PET/CT to detect bone marrow infiltration in patients with initial DLBCL［J］.Journal of Practical Oncology,2018,33（5）：480-485.
［10］ ZHANG W,FENG J,ZENG W,et al.Integrated analysis of the prognostic and oncogenic roles of OPN3 in human cancers［J］.BMC Cancer，2022，22(1):187.
［11］ ZHANG LH,ＫOSEK J,WANG M,et al.Lenalidomide efficacy in acti-Vated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression［J］.Br J Haematol,2013,160(4)：487-502.
［12］ GODFREY JK,NABHAN C,KARRISON T,et al.Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2［J］.Cancer,2019,125(11):1830-1836.
［13］ BALUAPURI A,WOLF E,EILERS M.Target gene-independent functions of MYC oncoproteins ［J］.Nature Reviews Molecular Cell Biology,2020,21(5):255-267.
［14］ FLOWERS CR,LEONARD JP,FOWLER NH.Lenalidomide in follicular lymphoma［J］.Blood，2020，135(24):2133-2136.
［15］ FACON T,KUMAR S,PLESNER T,et al.MAIA trial investigators.Daratumumab plus lenalidomide and dexamethasone for untreated myeloma［J］.N Engl J Med，2019，380(22):2104-2115.
［16］ LEONARD JP,TRNENY M,IZUTSU K,et al.AUGMENT:A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma［J］.J Clin Oncol，2019，37(14):1188-1199.
［17］ HANSEN JD,CORREA M,NAGY MA,et al.Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma［J］.J Med Chem，2020，63(13):6648-6676.
［18］ BJORKLUND CC,KANG J,AMATANGELO M,et al.Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN［J］.Leukemia，2020，34(4):1197-1201.
［19］ MOON H,MIN C,KIM G,et al.Crbn modulates calcium influx by regulating Orai1 during efferocytosis［J］.Nat Commun，2020，11(1):5489.
［20］ YAMAMOTO J,ITO T,YAMAGUCHI Y,et al.Discovery of CRBN as a target of thalidomide:a breakthrough for progress in the development of protein degraders［J］.Chem Soc Rev，2022，51(15):6234-6250.
［21］ SURKA C,JIN L,MBONG N,et al.CC-90009,a novel cereblon E3 ligase modulator,targets acute myeloid leukemia blasts and leukemia stem cells［J］.Blood，2021，137(5):661-677.
［22］ BARANKIEWICZ J,SZUMERA-CIECKIEWICZ A,SALOMON-PERZYNSKI A,et al.The CRBN,CUL4A and DDB1 expression predicts the response to immunomodulatory drugs and survival of multiple myeloma patients［J］.J Clin Med,2021,10(12):2683.
［23］ KIM MJ,MIN Y,SHIM JH,et al.CRBN is a negative regulator of bactericidal activity and autophagy activation through inhibiting the ubiquitination of ECSIT and BECN1［J］.Front Immunol,2019,10:2203.

Memo

Memo:
贵州省科技计划项目经费资助（编号：黔科合基础-zk［2022］一般420）
Last Update: 2023-11-30